# Jiangsu Alphamab Biopharmaceuticals trials: 38 (2026)

ClinicalTrials.gov lists 38 trials with Jiangsu Alphamab Biopharmaceuticals Co., Ltd as lead sponsor, 16 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Jiangsu Alphamab Biopharmaceuticals Co., Ltd: 38 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jiangsu-alphamab-biopharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 16
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 1, 2026 | NCT07797153 | JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Not yet recruiting | Recurrent or Metastatic Cervical Cancer | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797153) |
| June 1, 2026 | NCT07617727 | A Phase I Study of JSKN021 in Advanced Solid Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Recruiting | Advanced Malignant Solid Tumors | 199 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617727) |
| April 16, 2026 | NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard... | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Recruiting | Triple Negative Breast Cancer | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533123) |
| March 27, 2026 | NCT07497074 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Cervical Cancer | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497074) |
| March 16, 2026 | NCT07475559 | JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Not yet recruiting | Advanced Solid Tumor Malignancies | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475559) |
| February 6, 2026 | NCT07391644 | A Study of JSKN027 in Patients With Advanced Solid Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Not yet recruiting | Advanced Malignant Solid Tumor | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391644) |
| January 13, 2026 | NCT07336771 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1/2 | Not yet recruiting | Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07336771) |
| December 18, 2025 | NCT07292402 | JSKN022 in Subjects With Advanced Malignant Solid Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Recruiting | Advanced Malignant Solid Tumors | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292402) |
| December 15, 2025 | NCT07283198 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced... | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer (NSCLC) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283198) |
| April 24, 2025 | NCT06942234 | Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1/2 | Recruiting | Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06942234) |
| March 11, 2025 | NCT06868732 | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Recruiting | Advanced Non-small Cell Lung Cancer | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06868732) |
| January 15, 2025 | NCT06775483 | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Advanced Non-small Cell Lung Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775483) |
| January 13, 2025 | NCT06770881 | JSKN033 in Chinese Subjects with Advanced Malignant Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1/2 | Not yet recruiting | Advanced Malignant Tumors | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06770881) |
| December 30, 2024 | NCT06751485 | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Not yet recruiting | Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751485) |
| September 19, 2024 | NCT06592417 | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Recruiting | Advanced Malignant Solid Tumor | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06592417) |
| January 26, 2024 | NCT06226766 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1/2 | Terminated | Advanced Solid Tumor | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226766) |
| October 12, 2023 | NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Recruiting | Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06079983) |
| February 27, 2023 | NCT05744427 | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1/2 | Active not recruiting | Advanced Solid Tumor | 725 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05744427) |
| June 15, 2022 | NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | Completed | Advanced Non-small Cell Lung Cancer | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05420220) |
| April 4, 2022 | NCT05309512 | Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 | Terminated | Advanced Solid Tumor | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05309512) |
| December 8, 2021 | NCT05149326 | KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Unknown | Advanced Pancreatic Ductal Adenocarcinoma | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05149326) |
| August 12, 2021 | NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2/3 | Terminated | Advanced Non-small Cell Lung Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05001724) |
| May 11, 2021 | NCT04881929 | Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | Unknown | Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04881929) |
| March 3, 2021 | NCT04778982 | Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Observational | Terminated | HER2-positive Metastatic Breast Cancer | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04778982) |
| October 26, 2020 | NCT04601610 | KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1/2 | Terminated | Advanced HCC | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04601610) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 7 |
| Phase 2 | 13 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Not yet recruiting | 9 |
| Completed | 8 |
| Recruiting | 7 |
| Terminated | 7 |
| Unknown | 6 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 6 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Uterine Cervical Neoplasms | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Stomach Neoplasms | 1 |
| Lymphoma | 1 |
| Ovarian Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Recurrence | 1 |
| Thymoma | 1 |
| Arthritis, Rheumatoid | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B transportation and storage companies in the United States](https://specstream.ai/data/businesses/b2b-transportation-and-storage-companies/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Pediatric cardiology practices in the United States](https://specstream.ai/data/businesses/pediatric-cardiology-practices/united-states)
- [Landscaping companies in the United States](https://specstream.ai/data/businesses/landscaping-companies/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
